? BIOINFORMATICS SHARED RESOURCE (BISR) The BISR is an essential shared resource that supports a wide range of studies with bioinformatics and computational biology needs, ranging from next generation sequencing (NGS) to data management in population science studies. Housed within the Department of BMI, the BISR's goal is to leverage a variety of informatics services, ranging from analysis of omics datasets to patient/participant-centered data instrumentation, access, and management tools and processes.
The Specific Aims of the BSR are to: 1) Provide state of the art bioinformatics and computational biology services; and 2) Provide OSUCCC investigators with services, expertise and access to technology platforms in support of heterogeneous and multi-dimensional biomedical data management requirements. Over the current grant cycle, Drs. Kevin Coombes (TT) and Lang Li (CB) assumed leadership of BISR, replacing Drs. Philip Payne and Jeffrey Parvin. During the current funding cycle, a Memorandum of Understanding (MOU) was established for the Department of Biomedical Informatics (BMI) and the OSUCCC to support 5 faculty at 10% per year for 3 years within BISR as they transition to grant funding, on a rolling basis, to provide non-chargeable, cancer focused bioinformatics work for OSUCCC membership and/or cancer focused researchers. Additional major changes for BISR include supporting the enhancement of the Genomics Shared Resource (GSR) to incorporate newly developed shared services with Nationwide Children's Hospital (NCH); and added capabilities to support studies involving data from single-cell sequencing, long-read (third generation) sequencing, metabolomics, and metagenomics. BISR has added five new faculty to support the areas of (1) computational optimization for drug sensitivity prediction (Cheng), (2) proteomics, and functional annotation of DNA non-coding regions (Zhang), (3) metabolomics and metagenomics (Mathe), (4) single-cell sequencing (Ma), and (5) long-read sequencing (Au). BISR supported Biospecimen Services Shared Resource (BSSR) projects (Total Cancer Care [TCC] and the Oncology Research Information Exchange Network [ORIEN]) by establishing a data warehouse of patient records with de-identified data. During the current funding cycle, the BISR supported 115 publications (25 > 10 impact factor), 134 users, and 32 NCI grants including 5 P01s, 2 P50s, 13 R01s, 3 R21s, 1 R50, 2 U01s, 1 U10, 1 UG1, involving members from all five programs. Over the next grant cycle, BISR will enhance services for ?integromics?, e.g., the integration of disparate source of both omics and clinical data. BISR will be a critical part of the Immune Monitoring and Discovery Platform (IMDP), an overarching approach for fostering interactions among shared resources for complex immuno-oncology projects. The annual budget of the BISR is $1,122,279, yet the CCSG request is $106,905. As such, the BISR leverages extensive institutional support and seeks only 9.5% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090004
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell LungĀ Cancer (NSCLC): A Statement Paper from theĀ IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
London, Cheryl A; Acquaviva, Jaime; Smith, Donald L et al. (2018) Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors. Clin Cancer Res 24:6396-6407

Showing the most recent 10 out of 2602 publications